Osivax
Osivax is a Clinical-stage biotech company
Osivax has raised €50M across 3 funding rounds from 4 investors, most recently a Series B round in Mar 2025. Based in Lyon, France; founded 2017; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€50M
€50,072,388
Funding rounds
3
Investors
4
distinct backers
Active since
2019-07
latest 2025-03
Funding by year
EUR raised per yearOsivax — funding by year — interactive chart.
Data table
| Osivax — funding by year | |
|---|---|
| 2019 | €8.0M |
| 2020 | €33M |
| 2025 | €9.5M |
Signals
High confidenceRaise-next likelihood56
base rate 48% for Series B
- ▲ In typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood11
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-03-04 | Series B | €9.5M | Meiji Seika Pharma | View deal → |
| 2020-07-09 | Other | €33M | Bpifrance,European Innovation Council | View deal → |
| 2019-07-01 | Series A | €8.0M | Meusinvest (Noshaq) | View deal → |
Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData